Cocchi Enrico, Fabbri Chiara, Han Changsu, Lee Soo-Jung, Patkar Ashwin A, Masand Prakash S, Pae Chi-Un, Serretti Alessandro
Department of Biomedical and NeuroMotor Sciences, University of Bologna, Bologna, Italy.
Department of Psychiatry, Korea University, College of Medicine, Seoul, Republic of Korea.
BMC Psychiatry. 2016 Apr 18;16:106. doi: 10.1186/s12888-016-0813-x.
Genome-wide association studies (GWAS) represent the current frontier in pharmacogenomics. Thousands of subjects of Caucasian ancestry have been included in previous GWAS investigating antidepressant response. GWAS focused on this phenotype are lacking in Asian populations.
A sample of 109 major depressive disorder (MDD) patients of Korean origin in antidepressant treatment was collected. Phenotypes were response and remission according to the Hamilton Rating Scale for Depression (HRSD). Genome-wide genotyping was performed using the Illumina Human Omni2.5-8 platform. The same phenotypes were used in the STAR*D level 1 (n = 1677) for independent replication. In order to corroborate findings and increase the comparability between the two datasets, three levels of analysis (SNPs, genes and pathways) were carried out. Bonferroni correction, permutations, and replication across samples were used to reduce the risk of false positives.
Among the genes replicated across the two samples (permutated p < 0.05 in both of them), CTNNA3 appeared promising. The inorganic cation transmembrane transporter activity pathway (GO:0022890) was associated with antidepressant response in both samples (p = 2.9e-5 and p = 0.001 in the Korean and STAR*D samples, respectively) and this pathway included CACNA1A, CACNA1C, and CACNB2 genes.
The present study supported the involvement of genes coding for subunits of L-type voltage-gated calcium channel in antidepressant efficacy across different ethnicities but replication of findings is required before any definitive statement.
全基因组关联研究(GWAS)代表了药物基因组学的当前前沿。先前调查抗抑郁反应的GWAS纳入了数千名高加索血统的受试者。针对亚洲人群缺乏聚焦于该表型的GWAS。
收集了109名接受抗抑郁治疗的韩国裔重度抑郁症(MDD)患者样本。根据汉密尔顿抑郁量表(HRSD),表型为反应和缓解。使用Illumina Human Omni2.5 - 8平台进行全基因组基因分型。在STAR*D 1级研究(n = 1677)中使用相同表型进行独立验证。为了确证研究结果并提高两个数据集之间的可比性,进行了三个层面的分析(单核苷酸多态性、基因和通路)。使用Bonferroni校正、置换以及跨样本验证来降低假阳性风险。
在两个样本中均重复出现的基因(二者的置换p值均<0.05)中,CTNNA3显示出前景。无机阳离子跨膜转运体活性通路(GO:0022890)在两个样本中均与抗抑郁反应相关(在韩国样本和STAR*D样本中,p值分别为2.9e - 5和0.001),并且该通路包括CACNA1A、CACNA1C和CACNB2基因。
本研究支持编码L型电压门控钙通道亚基的基因在不同种族的抗抑郁疗效中发挥作用,但在做出任何确定性陈述之前,需要对研究结果进行重复验证。